Observational studyBMC cancer2023

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma.

Chieh-Lung Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.